Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- New Brunswick, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 29 Jul 2022
- Ended
- 5 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Gemcitabine and Capecitabine
- Record updated
- 7 May 2026
- Why it stopped
- No patients enrolled
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Histologically and/or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma
- Neoadjuvant chemotherapy (for at least three months) ± chemoradiation followed by R0 surgical resection
- Eastern Cooperative Oncology Group(ECOG) Performance status of PS 0 - 2
- At least 18 years of age
- Adequate bone marrow and organ functions as defined by:; Absolute neutrophil count ≥ 1000 cells/ μL; Hemoglobin ≥ 8 g/ dL; Platelets > 75,000 / μL; Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault; Total bilirubin ≤1.5 ULN; AST/ ALT < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
- Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately
- Ability to understand the nature of this study protocol and give written informed consent
- Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures
Who cannot take part
- Receipt of any investigational agents at the time of registration
- Major surgery within the 4 weeks prior to initiation of study treatment
- Presence of metastatic disease or malignant ascites on diagnostic imaging
- Presence of any additional active malignancy within the past 3 years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure (NYHA classification grade III or IV), unstable angina or active arrhythmia
- A history of allergy or hypersensitivity to any of the study drugs
- Severe hepatic impairment
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Pregnancy
- Participants with known malabsorption
Where in United States
- Rutgers Cancer Institute of New JerseyNew Brunswick, United States
About the trial
What the trial wants to find out
Primary Objectives:
Read full original descriptionShow less
To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone.
Secondary Objectives:
To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS).
To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates.
To assess the quality of life in patients receiving the study treatment.
The 2 groups in the trial
- Group 1- Gemcitabine and Capecitabine TreatmentTreatment being tested
Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes Day 1 - Day 21 • Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal.
Treatment: Gemcitabine and Capecitabine
- Group 2 - ObservationalNo study treatment, for comparison
Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy. If cancer returns during observation, there will be offered standard of care therapy. Follow-up visits will be every three months.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 May 2026